Share class: Sensus Healthcare, Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 17,036,845 13,274,659 ( 77.92 %) 541,449 ( 3.178 %) 77.92 %

Major shareholders: Sensus Healthcare, Inc.

NameEquities%Valuation
7.598 %
1,245,280 7.598 % 6 M $
7.171 %
1,175,293 7.171 % 6 M $
Vanguard Global Advisers LLC
4.515 %
740,022 4.515 % 4 M $
DFA Australia Ltd.
3.166 %
518,897 3.166 % 2 M $
Acadian Asset Management LLC
2.872 %
470,713 2.872 % 2 M $
Renaissance Technologies LLC
1.584 %
259,634 1.584 % 1 M $
Morgan Stanley Capital Services LLC
1.192 %
195,304 1.192 % 925 741 $
Geode Capital Management LLC
0.9161 %
150,151 0.9161 % 711 716 $
0.876 %
143,570 0.876 % 680 522 $
BNY Mellon Investment Adviser, Inc.
0.8662 %
141,971 0.8662 % 672 943 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░
░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional22.37%
Individuals17.87%
Other2.58%
State Street Corp.0.37%
Unknown56.81%

Based on 1000 largest holdings

Geographical origin of shareholders

United States
20.34%
Individuals
17.87%
Australia
3.17%
United Kingdom
1.21%
Switzerland
0.39%
Ireland
0.14%
France
0.08%

Based on 1000 largest holdings

Logo Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.
Employees
54
More about the company